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ess: lesley.p.kahl@gsk.cSummary In accordance with the Montreal Protocol 1987, initiatives to phase out
and replace ozone-depleting chlorofluorocarbon (CFC) propellants with non-ozone-
depleting propellants in metered-dose inhalers (MDIs) in the treatment of asthma
and chronic obstructive pulmonary disease are underway. In view of this, two multi-
centre, randomised, parallel-group, double-blind studies were conducted to
compare the safety and efficacy of salmeterol xinafoate delivered by an MDI using
the hydrofluoroalkane (HFA) 134a propellant with the licensed CFC formulation
(SereventTM) in asthmatic populations of children (4–11 years) and adults (X12
years). Patients on a stable dose of inhaled corticosteroids with a scope for
improvement based on mean morning peak expiratory flow (PEF) and symptoms were
randomised to receive salmeterol HFA MDI 50 mg twice daily or salmeterol CFC MDI
50 mg twice daily for 12 weeks. The primary efficacy variable was mean morning PEF
and secondary variables included other lung function parameters, symptom scores,
use of relief medication and safety assessments.
The difference between the treatments in adjusted mean morning PEF
(salmeterol HFA–salmeterol CFC) were 2.5 and 3.2 L/min for per-protocol
populations of children and adults, respectively. The lower limit of 95% confidence
intervals for both populations was within the pre-defined limit (15 L/min) set for
non-inferiority. Similar results were observed in intent-to-treat (ITT) populations.
In children, the two formulations resulted in a lack of any statistically significant
difference in secondary efficacy parameters. A significant difference at endpoint in
clinic forced expiratory volume in 1 s was reported in favour of the HFA formulation
in the adult population, although the magnitude of this effect was not considered
clinically significant. The incidences of adverse events (AEs) were similar for bothElsevier Ltd. All rights reserved.
SmithKline Research and Development.
8966 5137; fax: +44 20 8966 8954.
om (L. Kahl).
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N. Chopra et al.S2formulations and populations, and no safety concerns were generated. Together
these data demonstrate salmeterol HFA MDI to be as effective as salmeterol CFC MDI
in adults and children.
& 2004 Elsevier Ltd. All rights reserved.Introduction
Metered-dose inhalers (MDIs) are common drug-
delivery devices used in the treatment of respira-
tory diseases, such as asthma and chronic obstruc-
tive pulmonary disease (COPD).1 For many years,
chlorofluorocarbons (CFCs) have been used as
medicinal aerosol propellants and solvents in MDIs
owing to their non-toxic, inert and non-flammable
properties. However, in accordance with the
Montreal Protocol 1987, which stipulates the phas-
ing out of compounds that deplete ozone,2 en-
deavours have been made by the pharmaceutical
industry to replace all CFC inhalers with alter-
natives, such as hydrofluoroalkanes (HFAs). Since
HFAs are non-toxic, non-flammable, odour-free and
chemically stable, they are considered to be an
appropriate replacement for CFCs.
Salmeterol xinafoate, a long-acting b2 agonist, is
licensed for the treatment of obstructive airway
disease in adults and children.3–5 The drug is
currently available through delivery via the Accu-
haler/Diskus, Diskhaler and MDI formulated with
CFC propellants 11 and 12 (SereventTM). More
recently, a CFC-free MDI formulation of salmeterol
has been developed, which uses 1,1,1,2-tetrafluor-
oethane (GR106642X; GlaxoSmithKline plc), an HFA
propellant more commonly referred to as HFA-
134a.
The pharmacology and toxicology of HFA-134a
have been extensively investigated and its safety
and tolerability confirmed in a series of single- and
multi-dose studies in healthy individuals.6–8 HFA-
134a has also been demonstrated to be at least as
safe and well tolerated as the CFC propellants 11
and 12.9,10
The transition from CFC- to HFA-containing
inhalers has already occurred with other asthma
medications, such as salbutamol,11–13 fluticasone
propionate14 and beclomethasone dipropionate,15
all of which have been successfully reformulated as
HFA preparations and shown to be as effective as
the CFC predecessor in adults and children.
The new salmeterol MDI device incorporates an
optimised container-closure system including a new
and robust valve, which has resulted in a CFC-free
formulation with comparable pharmacokinetic and
pharmacodynamic profiles to the conventional CFC
formulation and an improved drug delivery.16,17The objective of the present research pro-
gramme was to compare the safety and efficacy
of the redeveloped MDI with the salmeterol and
HFA-propellant formulation with the existing sal-
meterol MDI propelled by CFCs at equal doses. This
was investigated in two separate clinical trials in
adults (SMO30006) and children (SMO30007) with
persistent asthma.Patients and methods
Patients
Study in adults
Adults with mild/moderate asthma aged 12 years
and older were eligible for study participation.
Patients were recruited in 52 centres in nine
countries (Estonia, Germany, Greece, Hungary,
Israel, Italy, Latvia, Poland and Romania).
Study in children
Children aged 4–11 years inclusive with mild/
moderate asthma were eligible for study entry.
Patients were recruited in 49 centres in 12
countries (as above but excluding Germany and
including Bulgaria, Croatia, France and the Uk-
raine).
All adult patients and the parents or legal
guardians of adolescents (12–17 years old) or
children provided written informed consent at the
start of the run-in period (visit 1) and prior to the
performance of any study-specific procedures.
Study design
Both studies were multi-centre, randomised,
parallel-group, double-blind clinical trials. Eligible
patients entered a 2-week run-in period, during
which they were instructed to take an HFA placebo
MDI, two puffs twice daily in the morning and in the
evening, in order to accustom themselves with
using the MDI. On entry to the treatment period,
patients were randomly assigned to receive either
salmeterol HFA MDI 50 mg twice daily or salmeterol
CFC MDI 50 mg twice daily and instructed to take
two puffs (25 mg per actuation) twice daily in the
morning and in the evening, approximately 12 h
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Salbutamol MDIs were also supplied for use as
rescue medication, and subjects were instructed to
continue taking their other permitted asthma
medication at the same dosage throughout
the study. Permitted medications included:
inhaled corticosteroids up to the maximum
permitted dose as described below for the
4-week period prior to the run-in period;
anti-leukotrienes; sodium cromoglycate; nedocro-
mil sodium; theophyllines; ketotifen and anti-
cholinergics.
Daily record cards (DRCs) were completed
throughout the run-in and treatment periods.
Patients were requested to complete the DRCs
each morning and evening. These may have been
completed by a parent/guardian if the patient was
unable to do this by him- or herself. Patients
attended the clinic at the beginning (visit 1) and
end of the run-in period (visit 2) and then after 4
(visit 3), 8 (visit 4) and 12 weeks (visit 5) of
treatment. There was a follow-up visit (visit 6),
approximately 2 weeks after visit 5. At each visit,
assessments of lung function and emergent adverse
events (AEs) were noted.
Criteria for entry into the 2-week run-in period in
both studies included: a documented clinical
history of asthma; and prior therapy for at least 4
weeks with beclomethasone diproionate (BDP) or
budesonide (BUD) at p 500 mg/day or fluticasone
propionate (FP) at p 200 mg/day for patients aged
4–11 years, or alternatively with BDP or BUD at p
1000 mg/day or FP at p 500 mg/day for patients
aged X 12 years. Patients were excluded if they
had received long-acting b2 agonists, oral b2
agonists, slow-release bronchodilators, any
combination therapy containing b2 agonists
or antibiotics to treat a respiratory tract infection
in the 2 weeks prior to visit 1. In addition,
their asthma medication should not have been
changed within 2 weeks of visit 1, and they should
not have been hospitalised or required oral,
parenteral or depot corticosteroids within 4 weeks
of visit 1.
At the end of the run-in period, patients with a
scope for improvement were eligible to enter the
treatment period if they had a daytime plus
nighttime symptom score totalling X1 on at least
4 of the last 7 days of the run-in and had a mean
morning peak expiratory flow (PEF), calculated
from the last 7 days of the run-in period, between
50% and 85% of their PEF measured 15min after
administration of 400 mg of VentolinTM. Patients
who had experienced an exacerbation of their
asthma during the run-in period were excluded
from the study.Methods
Regulatory and Ethics committee approval was
obtained for both studies and for each participating
centre. Both studies were designed in accordance
with the Committee for Proprietary Medical Pro-
ducts guidelines (Replacement of chlorofluorocar-
bons [CFC] in MDI products, 1993) and both were
conducted in accordance with good clinical prac-
tice guidelines and the Declaration of Helsinki,
1996.Measurement of lung function
Prior to use of rescue or study medication,
patients were requested to make three PEF
measurements and record the highest value in the
DRC each morning on rising and each evening
before going to bed. PEF was measured on a Mini-
Wright peak flow meter (Clement Clark Interna-
tional Ltd, Harlow, UK) and recorded in litres per
minute.
At visits 1, 2, 3, 4 and 5, forced expiratory
volume in 1 s (FEV1) was measured from flow
volume curves generated by spirometery in the
clinic and recorded in litres.DRC data
Each day, patients recorded morning and evening
PEF, the number of occasions that relief medication
was used during the previous day and night, and
asthma symptom scores. A patient’s assessment of
asthma symptoms during the day was recorded
using a 0–5 rating scale, while nighttime symptom
scores were rated on a 0–4 scale, where ratings of 5
and 4 indicated very severe symptoms on the
respective scales.Safety assessments
Safety was assessed by the recording of all
AEs and serious adverse events (SAEs), by
checking vital signs (systolic and diastolic blood
pressure and pulse rate) and through physical
examinations.Statistical methods
Sample sizes
For the adult study, a previous investigation
comparing the non-optimised container-closure
system MDI of salmeterol HFA with salmeterol CFC
in adults provided an estimate of variance (SD) for
mean morning PEF averaged over weeks 1–12 of
44.1 L/min.18 Assuming a non-inferiority limit of
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two-sided t-test, it was shown that the number of
patients required in the per-protocol (PP) popula-
tion to demonstrate non-inferiority was 182 per
treatment group. To accommodate for a 10%
exclusion rate from the ITT population, 204
patients were planned to be randomised per
treatment group.
For the study in children, a previous investigation
comparing the non-optimised container-closure
system MDI of salmeterol HFA with salmeterol CFC
in children provided an estimate of variance (SD) for
mean morning PEF averaged over weeks 1–12 of
47.9 L/min.19 Making the same assumptions as for
the adult study, the number of patients required in
the PP population to demonstrate non-inferiority
was 215 per treatment group. To accommodate for
a 10% exclusion rate from the ITT population, 240
patients were planned to be randomised per
treatment group.Efficacy analysis
For both studies, the primary population for the
primary efficacy analysis was the PP population.
The ITT population was used for confirmatory
analysis of the primary efficacy endpoint and as
the primary population for all other efficacy end-
points and safety analysis. As the primary efficacy
endpoint, differences between the treatment
groups for mean morning PEF over weeks 1–12
were assessed using analysis of covariance, with
factors for treatment, country and spacer use, and
age, sex and baseline mean morning PEF as
covariates. The difference between treatments
was calculated and the associated 95% confidence
interval derived. To demonstrate non-inferiority,
this interval had to have a lower limit of greater
than 15 L/min for both the PP and ITT popula-
tions. Analysis of other lung function parameters,
mean symptom scores and use of rescue medication
was performed in a similar manner. For the
paediatric study, subjects only provided an assess-
ment of FEV1 if they were over 7 years old, or if
younger were capable of using a spirometer.
Analysis of percentage of symptom-free days and
nights and percentage rescue medication-free days
and nights was performed following categorisation
using logistic regression with the same factors in
the model.
Safety data were collated and summarised by
treatment group. AEs were coded using the MedDRA
dictionary, and the numbers of subjects in
each treatment group reporting each event were
calculated.Results
Withdrawals
Study in adults
Six hundred and thirty-six patients were
recruited into the study. Of these, 64 patients
were withdrawn prior to randomisation. The
most common reasons for withdrawal were
patients not fulfilling entry criteria ðn ¼ 36Þ or
withdrawing consent ðn ¼ 12Þ: Of the 572 subjects
who were randomised and received at least one
dose of study medication (ITT population, HFA
group ¼ 278, CFC group ¼ 294), 40 patients
were withdrawn: 17 from the salmeterol HFA
group and 23 from the salmeterol CFC group.
The most common reasons for withdrawal were
protocol violations ðn ¼ 13Þ and consent withdrawal
ðn ¼ 10Þ:
Of the 572 subjects in the ITT population, 53
patients were totally excluded from the PP
population owing to major protocol violations: 20
patients from the salmeterol HFA group and
33 patients from the salmeterol CFC group.
The most common reasons for exclusion included
having a mean PEF p50% of predicted normal
ðn ¼ 15Þ and insufficient symptom scores X1
recorded in DRCs.Study in children
Six hundred and thirty-nine patients were re-
cruited into the study. Of these, 92 patients were
withdrawn prior to randomisation. The most com-
mon reasons were that patients did not fulfil the
entry criteria ðn ¼ 62Þ or they withdrew consent
ðn ¼ 18Þ: Five hundred and forty-seven patients
were randomised and 546 received at least one
dose of study medication (ITT population, HFA
group ¼ 274, CFC group ¼ 272). Eighteen were
withdrawn following randomisation, eight from
the salmeterol HFA group and 10 from the salme-
terol CFC group. AEs were the most common reason
for withdrawal, occurring in six patients from the
salmeterol HFA group and five patients from the
salmeterol CFC group.
Of the 546 subjects in the ITT population, 45
patients were totally excluded from the PP
population owing to major protocol violations: 26
patients from the salmeterol HFA group and 19
patients from the salmeterol CFC group. The most
common reasons for exclusion included not meeting
the inhaled steroid criteria at run-in ðn ¼ 18Þ and
having insufficient symptom scores X1 recorded in
DRCs during run-in ðn ¼ 16Þ:
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study populations
Demography and baseline characteristics were
well matched between treatment groups in the
populations of both studies (Table 1). In children,
the majority of patients in both treatment groups
had a history of asthma for at least 2 years, while in
the adult population the majority of patients in
both treatment groups had a history of asthma for
at least 5 years. In both study populations, the
treatment groups represented relatively stable,
well-defined populations with comparable baseline
lung function (PEF, percentage predicted PEF and
FEV1). Both studies showed similar baseline symp-
tom scores and use of relief medication in the twoTable 1 Demographic and baseline characteristics of ad
Parameter
Adult population
Mean age (year) (SD)
Males (%)
Current/former smokers (%)
Asthma X5 years (%)
Use of ICS at allowable dosage prior to run-in periody
Use of ICS during the study period
Mean % predicted FEV1(SD)
Mean % predicted PEF (SD)
Mean morning PEF (L/min) (SD)
Mean evening PEF (L/min) (SD)
Mean daytime symptom score (SD)
Mean nighttime symptom score (SD)
Mean use of relief medication in 24 h (SD)
Parameter
Paediatric population
Mean age (year) (SD)
Males (%)
Asthma X2 years (%)
Use of ICS at allowable dosage prior to run-in periodz
Use of ICS during the study period
Mean % predicted FEV1 (SD)
Mean % predicted PEF (SD)
Mean morning PEF (L/min) (SD)
Mean evening PEF (L/min) (SD)
Mean daytime symptom score (SD)
Mean nighttime symptom score (SD)
Mean use of relief medication in 24 h (SD)
Data given for intent-to-treat populations.
yAdult patients were eligible for entry into the run-in period if t
or FP at p500 mg/day. Use of these medications up to the maxim
zPaediatric patients were eligible for entry into the run-in pe
500mg/day or FP atp200mg/day. Use of these medications up to ttreatment groups. Co-morbidities and concurrent
medication use were also similar in the two
treatment groups.
Mean morning PEF
Mean morning PEF values derived from DRC
readings were analysed for both PP and ITT
populations. In the PP populations of both adults
and children, increases in mean morning PEF over
weeks 1–12 were observed in both salmeterol HFA
and salmeterol CFC treatment groups (Fig. 1).
In the adult PP population, the overall improve-
ments in mean morning PEF, adjusting for age, sex,
country, baseline mean morning PEF and spacer use,
were 37.4 and 40.5 L/min in the salmeterol HFA andult and paediatric populations.
Salmeterol HFA Salmeterol CFC
ðn ¼ 278Þ ðn ¼ 294Þ
46.2 (15.5) 47.2 (15.3)
126 (45) 121 (41)
80 (29) 86 (29)
208 (75) 214 (73)
275 (99%) 291 (99%)
276 (499%) 291 (99%)
80.1 (17.8) 78.5 (19.8)
81.1 (18.1) 80.1 (18.2)
367.0 (102.5) 356.0 (102.5)
375.2 (105.4) 365.5 (106.6)
1.31 (0.77) 1.38 (0.71)
0.86 (0.64) 0.86 (0.62)
1.67 (1.50) 1.81 (1.44)
Salmeterol HFA Salmeterol CFC
ðn ¼ 274Þ ðn ¼ 272Þ
7.4 (2.2) 7.3 (2.2)
165 (60) 163 (60)
186 (68) 204 (75)
263 (96%) 265 (97%)
274 (100%) 272 (100%)
85.8 (15.1) 87.2 (14.7)
87.4 (21.0) 88.2 (19.1)
212.8 (62.2) 214.0 (70.1)
221.6 (62.9) 221.3 (70.4)
1.03 (0.65) 0.99 (0.65)
0.68 (0.48) 0.70 (051)
1.01 (1.08) 0.99 (0.91)
hey had used for at least 4 weeks BDP or BUD atp1000mg/day
um dosage were permitted during the study period.
riod if they had used for at least 4 weeks BDP or BUD at p
he maximum dosage were permitted during the study period.
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Figure 1 Mean morning PEF (per protocol population) in
(a) adults and (b) paediatrics.
Table 2 Lung function data over weeks 1–12 in adult an
Parameter Salmetero
Adult population
Adjusted mean change from baseline (SD)
Morning PEF (L/min) 37.4 (2.8)
ðn ¼ 245Þ
Morning PEF (L/min) 35.7 (2.7)
ðn ¼ 276Þ
Evening PEF (L/min) 32.7 (2.6)
ðn ¼ 276Þ
Clinic FEV1 (L) at endpoint 0.269 (0.0
ðn ¼ 277Þ
Paediatric population
Adjusted mean change from baseline (SD)
Morning PEF (L/min) 37.2 (2.1)
ðn ¼ 246Þ
Morning PEF (L/min) 35.8 (2.1)
ðn ¼ 274Þ
Evening PEF (L/min) 31.8 (2.0)
ðn ¼ 274Þ
Clinic FEV1 (L) at endpoint 0.151 (0.0
ðn ¼ 193Þ
All values adjusted for age, sex, country, baseline mean morning
Per-protocol population; all other parameters looked at inten
yP ¼ 0.008; for all other treatment differences P40.05.
N. Chopra et al.S6salmeterol CFC groups, respectively (Table 2). The
estimated treatment difference (salmeterol HFA–
salmeterol CFC) was 3.2 L/min and the 95%
confidence interval was (9.8–3.4). The lower limit
of this was within the pre-defined non-inferiority
limit of 15 L/min, indicating that the HFA formula-
tion is at least as effective as the CFC formulation.
For the ITT population, the 95% confidence interval
was (8.9–3.7), which further demonstrated non-
inferiority of the HFA formulation.
In the PP population of children, the overall
improvement in the salmeterol HFA group was
37.2 L/min and in the salmeterol CFC group,
34.7 L/min (Table 2). The estimated treatment
difference was 2.5 L/min and, as observed in the
adult study, the 95% confidence interval (2.8–7.8)
was within the pre-defined non-inferiority limit of
15 L/min, demonstrating that the HFA formula-
tion was not inferior to the CFC formulation. The
95% confidence interval for the ITT population also
demonstrated non-inferiority (Table 2).Mean evening PEF
No significant treatment differences between
salmeterol HFA and salmeterol CFC were observedd paediatric populations.
l HFA Salmeterol CFC Treatment difference
(95% confidence interval)
40.5 (2.9) 3.2 (9.8, 3.4)
ðn ¼ 244Þ
38.3 (2.7) 2.6 (8.9, 3.7)
ðn ¼ 291Þ
34.1 (2.6) 1.4 (7.3, 4.7)
ðn ¼ 291Þ
27) 0.183 (0.027) 0.085 (0.022, 0.148)y
ðn ¼ 290Þ
34.7 (2.2) 2.5 (2.8, 7.8)
ðn ¼ 248Þ
33.8 (2.1) 2.0 (3.2, 7.2)
ðn ¼ 270Þ
30.6 (2.1) 1.2 (3.9, 6.4)
ðn ¼ 270Þ
19) 0.148 (0.020) 0.003 (0.047, 0.052)
ðn ¼ 185Þ
PEF, baseline clinic FEV1 for FEV1 at endpoint and spacer use.
t-to-treat population.
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over the 12-week study period (Table 2).Clinic FEV1
No significant difference in clinic FEV1 at end-
point was observed between salmeterol HFA and0.2
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Figure 2 Other diary card measures over weeks 1–12 in
adults (a) and paediatrics (b).
Table 3 Comparison of symptom- and relief medication
and paediatrics.
Parameter
Adult population
% Symptom-free days
% Relief medication-free days
% Relief medication-free nights
Paediatric population
% Symptom-free days
% Relief medication-free days
% Relief medication-free nights
Odds ratio41 indicates more symptom-free and relief medicatio
P40.05. Data given for intent-to-treat populations.salmeterol CFC in the ITT population of children
(Table 2). In the adult ITT population, a significant
difference of 0.085 L in clinic FEV1 between these
treatment groups was observed at endpoint in
favour of the HFA formulation (P ¼ 0:008; Table 2).
Symptom scores and use of relief medication
Mean daytime and nighttime symptom scores as
well as daily use of relief medication were reduced
by both salmeterol formulations in adults and
children (Fig. 2). The adjusted mean change from
baseline in all three DRC measures following
salmeterol HFA or salmeterol CFC were compar-
able, and no statistically significant treatment
differences were observed in either population
(P40:05; Table 3).
Safety
Overall, both treatment formulations were well
tolerated in adults and children and had compar-
able AE profiles (Table 4). In the adult study, of the
572 patients in the ITT population, 216 were
reported as having an AE: 106 (38%) in the
salmeterol HFA group and 110 (37%) in the
salmeterol CFC group. Of these, two (o1%)
patients receiving salmeterol HFA and six (2%)
patients receiving salmeterol CFC reported having
SAEs, with less than 1% having an SAE leading to
withdrawal. No more than 1% of patients in either
treatment group reported a specific drug-related
AE.
In the study with children, of the 546 patients in
the ITT population, 301 were reported as having an
AE: 157 (57%) in the salmeterol HFA group and 144
(53%) in the salmeterol CFC group. There were no-free days between salmeterol formulations in adults
Salmeterol HFA : salmeterol CFC
odds ratio (95% confidence interval)
1.16 (0.84, 1.60)
1.11 (0.79, 1.57)
1.23 (0.84, 1.81)
0.94 (0.66, 1.34)
0.85 (0.55, 1.31)
0.72 (0.43, 1.22)
n-free days.
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Table 4 Commonly reported adverse events (X5% ITT population) in adults and paediatrics.
Adverse event Salmeterol HFA Salmeterol CFC
ðn ¼ 278Þ ðn ¼ 294Þ
Adult population
No. (%) reporting an on-treatment AE 98 (35) 100 (34)
Asthma exacerbation 24 (9) 26 (9)
Headache 21 (8) 19 (6)
Nasopharyngitis 15 (5) 7 (2)
Adverse event Salmeterol HFA Salmeterol CFC
ðn ¼ 274Þ ðn ¼ 272Þ
Paediatric population
No. (%) reporting an on-treatment AE 146 (53) 134 (49)
Asthma exacerbation 16 (6) 10 (4)
Headache 26 (9) 22 (8)
Cough 18 (7) 22 (8)
Nasopharyngitis 20 (7) 20 (7)
Rhinitis NOS 23 (8) 17 (6)
Pyrexia 19 (7) 15 (6)
N. Chopra et al.S8SAEs reported in patients receiving salmeterol HFA,
and only two patients in the salmeterol CFC group
(o1%) reported an SAE that led to withdrawal. No
more than 2% of patients in either treatment group
reported a specific drug-related AE.
The most common AEs (occurring in X5% of the
ITT population) during treatment in adults and
children are given in Table 4. The incidences were
found to be low and comparable across treatment
groups with the exception of nasopharyngitis in
adults, the incidence of which in the salmeterol
HFA group was more than double that in the
salmeterol CFC group.
No differences in vital signs between treatment
groups were reported. No deaths occurred during
either of the two studies.Discussion
The studies described illustrate that substantial
clinical efficacy may be achieved with salmeterol
at a dose of 50 mg twice daily when administered
via an MDI using either a CFC or HFA propellant. The
HFA device evaluated represents an improvement
on an earlier investigational HFA MDI.20 Further-
more, the magnitude of the clinical improvements
from baseline values observed with both treat-
ments was therapeutically similar, as evidenced by
statistical non-inferiority of the primary and sec-
ondary efficacy parameters assessed.
In line with previous data, the magnitude of
improvements in the primary efficacy variable,mean morning PEF, was deemed clinically mean-
ingful.21 Furthermore, no statistically significant
differences between the two formulations were
observed in mean morning PEF, in either popula-
tion, as the lower limits of the 95% confidence
intervals were above the pre-defined 15 L/min
non-inferiority limit. These results indicated com-
parable efficacy between the HFA and CFC for-
mulations of salmeterol.
Similarly, no statistically significant differences
between the two treatments were observed in any
of the secondary efficacy parameters in children.
Although a statistically significant difference be-
tween treatments was observed in clinic FEV1 at
endpoint in adults, this was not deemed clinically
relevant, as the treatment difference was only
85mL (95% confidence interval: 0.022–0.148 L). A
clinically meaningful treatment difference in FEV1
for asthmatics is considered to be an improvement
from baseline of approximately 200mL.22 The
observed treatment difference for the salmeterol
HFA–salmeterol CFC comparison and the upper
limit of the confidence interval were well below
this clinically meaningful improvement. Marked
improvements from baseline in daytime and night-
time symptom scores and daily use of relief
medication were observed with both treatments,
further illustrating the efficacy of salmeterol in
therapy of asthma.
In accordance with requirements for demonstra-
tion of equivalence in clinical trials,23 baseline and
eligibility characteristics of the population under
study showed that there was room for clinical
improvement of lung function and asthma
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avoiding a conclusion of equivalence through non-
response. Additionally, the observed mean improve-
ments in the clinical parameters evaluated were
consistent between the ITT and PP populations,
thereby confirming the validity of the study results.
The two formulations of salmeterol were well
tolerated and demonstrated comparable tolerabil-
ity profiles, with the formulations exerting similar
incidences of AEs, which were not unexpected for
the populations under investigation. The higher
incidence of nasopharyngitis observed in adults
receiving salmeterol HFA compared with salmeterol
CFC (5% versus 2%) was not regarded as being
clinically relevant as this event was common for the
time of year in which the study took place (early
spring) and was not considered to be drug-related.
The comparable efficacy and tolerability profiles of
the salmeterol HFA and salmeterol CFC formula-
tions, therefore, facilitate a seamless transition to
the new CFC-free inhalers.
In addition to demonstrating comparable efficacy
and safety, this study has reinforced the effective-
ness of salmeterol in the treatment of obstructive
lung disease in both adults and young children.
Salmeterol CFC is approved for long-term, twice-
daily maintenance treatment of obstructive air-
ways diseases, including asthma and COPD, and for
the prevention of exercise-induced bronchospasm.
The operation of an MDI is independent of a
patient’s diagnosis, and the pharmacological me-
chanism of salmeterol is the same for asthma and
COPD. While comparable efficacy of the HFA
formulation and the CFC formulation of salmeterol
was demonstrated in asthmatic populations in this
study, there is no reason to anticipate that the
effects of the salmeterol HFA inhaler will differ
from those of the CFC inhaler in terms of
bronchodilator efficacy in patients with COPD. This
is because other drug classes, redeveloped from
CFC- to HFA-containing inhalers, have shown similar
clinical benefits in COPD.24
In summary, this study has shown that children
and adults with persistent asthma may be switched
from the salmeterol CFC MDI (Serevent) to the
salmeterol HFA MDI with maintenance of good
clinical efficacy and tolerability profiles. Further-
more, it provides assurance of the continued
availability of salmeterol via an HFA MDI.Acknowledgements
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